Tacrine hydrochloride hydrate

A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. (In Vitro) :Tacrine hydrochloride (hydrate) (12.5 to 37.5 nM) inhibits venom acetylcholinesterase as well as human serum butyrylcholinesterase in a concentration-dependent manner. The IC50 is 31 nM for snake venom AChE and 25.6 nM for human BChE. (In Vivo) :Pretreatment with Tacrine hydrochloride (hydrate) also modifies absolute levels of cocaine self-administration during reacquisition. Body weight declines approximately one-half percent over four days of treatment with intravenous Tacrine hydrochloride (hydrate) . Delivery of Tacrine hydrochloride (hydrate) by osmotic pump does not alter either linear- or repeated- cocaine-induced locomotor activity. There is no significant main effect or interaction with Tacrine hydrochloride (hydrate) treatment on active lever responding during reinstatement. Post hoc comparisons indicate that rats self-administering cocaine has significantly lower alkaline phosphatase levels, relative to TTacrine hydrochloride (hydrate) - but not saline- treated rats evaluated by conditioned-place preference.

206658-92-6

Pharmacology & Drug Discovery

>98% (HPLC)

Soluble in Water

O.Cl.NC1=C2CCCCC2=NC2=CC=CC=C12

C13H14N2·HCl·XH2O

234.72

Storage temperature: -20°C. Stability: ≥ 2 years